Markets
OPK

Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA

Using a smartphone to calculate data

Becton, Dickinson and CompanyBDX , also known as BD, recently announced the FDA 510(k) clearance of its BD MAX enteric viral panel, a molecular diagnostic test for the direct qualitative detection and differentiation of enteric viral pathogens that cause viral gastroenteritis. This is also likely to boost BD's Diagnostic Systems apart from fortifying its foothold in the infectious disease diagnostics market.

However, the latest development failed to drive BD's shares, which dipped 1.5% to $214.26 at close.

More on BD MAX

For investors' notice. the BD MAX enteric viral panel is designed for targeted detection of the viral cause of infectious diarrhea symptoms in all care settings. Notably, it runs on the BD MAX system, which is a fully-integrated, automated molecular diagnostics platform.

In fact, earlier this year, the company obtained CE Mark for molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the BD MAX System. (Read More: BD's CE Mark and Check-Point's Screening Test to Fight CPO )

BD Diagnostic Systems at a Glance

BD Diagnostic Systems provides products and instruments for detecting a broad range of infectious diseases, healthcare-associated infections and cancer. BD MAX majorly drove the segment's revenues in the last reported quarter.

With the latest development, BD now has a wide portfolio of solutions for the detection of infectious diseases.

Last month, BD's Phoenix CPO detect test received FDA 510(k) clearance. (Read More: BD's FDA Nod for Phoenix Test Boosts Diagnostic Systems )

Market Prospects

Zion Market Research predicts that the global infectious disease diagnostics market will reach a worth of $21.28 billion by 2024 at a CAGR of 5.4%.

Hence the latest development has been a well-timed one for BD.

Shares Shine Bright

Over the past year, shares of BD have rallied 3.7% against the industry 's 11.4% decline. The current level also compares favorably with the S&P 500 index's 8% fall.

Zacks Rank & Key Picks

BD currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Veeva Systems Inc. VEEV , Integer Holdings Corporation ITGR and OPKO Health, Inc. OPK .

Veeva Systems' long-term earnings growth rate is projected at 19.5%. The stock currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Integer projects earnings growth rate of 31.2% for the fourth quarter. It currently carries a Zacks Rank #1.

OPKO Health's long-term earnings growth rate is projected at 12%. The stock presently sports a Zacks Rank of 2 (Buy).

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Veeva Systems Inc. (VEEV): Free Stock Analysis Report

Integer Holdings Corporation (ITGR): Free Stock Analysis Report

OPKO Health, Inc. (OPK): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

OPK BDX VEEV ITGR

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More